On January 27, 2022, Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. Wilson Sonsini Goodrich & Rosati advised SR One on corporate and IP matters related to the transaction.
“We intend to become a leader in creating the next-generation of cytokine immunotherapies, and this investment from a phenomenal group of blue-chip firms represents a major endorsement of our progress to date and future potential," said Aaron Ring, MD, PhD, Simcha Therapeutics Founder and Assistant Professor of Immunobiology at the Yale School of Medicine. "The Series B comes at a pivotal time in Simcha's development as we have transitioned to a clinical-stage company and continue to build our leadership team.”
The Wilson Sonsini team that advised SR One on the transaction includes:
Corporate:
Dan Koeppen
Meg Burton
Tim Conroy
For more information, please see Simcha Therapeutics’ press release.